eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2018
vol. 35
 
Share:
Share:
abstract:
Review paper

Quo vadis, biological treatment for psoriasis and psoriatic arthritis?

Barbara Olszewska
,
Zygmunt Adamski
,
Magdalena Czarnecka-Operacz

Adv Dermatol Allergol 2018; XXXV (3): 231-237
Online publish date: 2018/06/18
View full text Get citation
 
Psoriasis is a chronic autoimmune disease that affects approximately 2–3% of the world’s population. Although the cutaneous manifestations of the disease are the most prevalent, psoriasis is also associated with a systemic inflammation and various co-morbidities linked with autoinflammatory processes. One of those processes is psoriatic arthritis, an inflammatory, seronegative spondyloarthropathy that develops in 13.8–30% of psoriatic patients at some point of their lives. Over the past 15 years the therapeutic options for severe and generalized psoriasis have broadened immensely with the introduction of biological agents to everyday practice. We present a quick overview of current biological therapies in the treatment of psoriasis and prospects for forthcoming advancements in biological treatment.
keywords:

psoriasis, biological treatment, biologics, psoriatic arthritis

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.